Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 20/20 | 0.75 |
| ▸ | OXTR | P30559 | 13/20 | 0.75 |
| ▸ | AVPR1A | P37288 | 13/20 | 0.75 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.61 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2499664 | 0.96 | AVPR1B (0.71) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2499170 | 0.95 | AVPR1B (0.71) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL7083545 | 0.94 | AVPR1B (0.83) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2494109 | 0.93 | AVPR1B (0.74) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2493599 | 0.91 | AVPR1B (0.66) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2494973 | 0.90 | AVPR1B (0.70) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2492705 | 0.90 | AVPR1B (0.71) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2499959 | 0.89 | AVPR1B (0.63) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2496884 | 0.89 | AVPR1B (0.70) | AVPR1BOXTRAVPR1AAVPR2GPR65 | |
| SCHEMBL2496086 | 0.88 | AVPR1B (0.79) | AVPR1BOXTRAVPR1AAVPR2GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | claimed |
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-8030499-B2 | 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-10-04 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318923-A1 | 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle | AVPR1B, AVPR1A, AVPR2 | AVPR1B 1/4885OXTR 37/4885AVPR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.